Inlyta
/
Inlyta (axitinib) is a targeted therapy classified as a tyrosine kinase inhibitor, indicated for the treatment of advanced renal cell carcinoma (kidney cancer) after prior therapy. It is administered as an oral tablet and is available by prescription only. Patients are advised to monitor for potential side effects, including hypertension, as Inlyta may raise blood pressure and should not be used in patients with uncontrolled hypertension.
FAQs about Inlyta
What should I do if I miss a dose?
If you miss a dose of Inlyta, take it as soon as you remember on the same day. However, if it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose. This information is provided in the Patient Counseling Information section of the label.
Can I take Inlyta while pregnant or breastfeeding?
Inlyta may cause harm to a developing fetus, and it is not recommended for use during pregnancy. Women who are pregnant or may become pregnant should discuss the risks with their healthcare provider. It is also advised that women should not breastfeed while taking Inlyta, as it is not known if axitinib passes into breast milk. This information is detailed in the Warnings and Precautions section of the label.
Can I stop taking Inlyta suddenly?
Patients are advised not to stop taking Inlyta without consulting their healthcare provider, as abrupt discontinuation may affect treatment outcomes. It is important to follow your prescriber\
25
commonly-prescribed
medication.